A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether the use of gene therapy could relieve angina symptoms in patients who are not amenable to conventional revascularisation strategies. Altogether 60 papers were identified using the search below. Seven papers presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results, and study weaknesses of the papers are tabulated. We conclude that, gene therapy for ischaemic heart disease is in its infancy with evaluation trials of novel vectors, delivery methods and targeted patient population. The initial results from the randomised clinical trials using gene therapy for severe CHD are interesting but clear benefits are yet to be demonstrated. Longer term outcomes from the AGENT trial and VIVA trials are awaited.
Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in the ICVTS w1x.
Clinical scenario
There are a number of patients with poor left ventricular function being referred to the cardiac surgeon with angina who have had previous multiple revascularisation procedures and are on maximal medical therapy. They are clearly unsuitable for further surgical revascularisation either due to diffuse coronary artery disease with poor targets or have no useable conduits. Although some of these patients may be eligible for orthotopic heart transplantation, current waiting times for donor hearts and limitations in organ availability render this option unlikely to occur before the patient has become severely ill and reached status I priority level. Gene based modalities for ischaemic myocardium may eventually constitute a therapeutic option for these patients.
You wish to find out what current evidence exists in this area of research.
Three-part question
In wpatients not amenable to conventional revascularisationx does wgene therapyx reduce the symptoms of wanginax.
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Search strategy
Medline 1990 to September 2005 using the OVID interface. wexp vascular endothelial growth factor AyOR vascular endothelial growth factor.mp OR VEGF.mp OR exp Fibroblast Growth FactorsyOR Fibroblast growth factor.mp OR FGF.mpx AND wExp Thoracic surgeryyOR Thoracic surgery.mp OR cardiac surgery.mp OR CABG.mp OR Coronary arter$ disease.mp OR myocardial.mpx limit to human.
Search outcome
Four hundred and sixty-four papers were found of which only 12 papers were clinically relevant. There were 7 cohort and 5 randomised trials. These papers are presented in Table 1 .
Comment(s)
Angiogenesis is a theoretically highly attractive strategy for patients for whom conventional revascularisation may not be an option. There are several agents that have been studied but Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) have been most studied in clinical trials. In addition, several methods of application have been studied, including intracoronary injection, percutaneous intramyocardial injection, intramyocardial injection via mini-thoracotomy and intramyocardial injection during coronary surgery. We identified seven cohort studies that initially reported highly positive results. Using a minithoracotomy Losordo w2x, Symes w3x Vale w4x, and Fortuin w9x all presented cohorts of patients followed up to 2 years post-injection. They found highly significant improvements in angina scoring, some improvements in exercise testing and even some angiographic or perfusion scanning benefits. Rosengart w5x reported initial findings on injection during coronary surgery and found some improvements in regional wall motion after injection.
While these studies were very positive, they suffered from a lack of control groups to compare their results with. We identified five randomised trials. Unfortunately their findings were less positive.
The AGENT trial w7x recruited 79 patients and utilised Ad5-FGF4 delivered via intracoronary catheter. They failed to show improvement in angina or myocardial contractility at 4 and 12 weeks. However, they did show 20-30% improvement in exercise tolerance test at 4 and 12 weeks compared to baseline.
The VIVA trial w8x recruited 178 patients and the primary outcome demonstrated significant improvement in angina class, frequency, QOL and ETT at 120 days post gene therapy using a dose of 50 ng.kg .min of rhVEGF. There was no correlation between subjective improvement and objective measurement of myocardial perfusion and ventricular ejection fraction. The FIRST Trial w12x recruited 337 patients to receive rFGF2 via an intracoronary 20 min infusion or placebo, in a double blinded study. Despite the large size of the study, they failed to show any benefits in treadmill testing, angina scores or on nuclear perfusion scanning.
The Euroinject One Trial w10x randomised 80 patients with 'no option' angina to VEGF injection or placebo. Both groups received 10 intramyocardial injections via a percutaneous route. No differences were found in symptoms, exercise testing, ejection fraction or myocardial perfusion scanning. A significant improvement was detected in local wall abnormalities, but this was the only positive finding.
The KAT Trialists w13x randomised 103 patients already undergoing stenting to receiving placebo or VEGF via intracoronary infusion. They found a significant improvement in myocardial perfusion scanning, although they found no difference in angiographic findings, or clinical outcomes.
Clinical bottom line
Gene therapy for ischaemic heart disease is in its infancy with evaluation trials of novel vectors, delivery methods and targeted patient population. The initial results from the randomised clinical trials using gene therapy for severe CHD are interesting but clear benefits are yet to be demonstrated. Longer term outcomes from the AGENT trial and VIVA trials are awaited.
